Short answer
Celldex Therapeutics, Inc. (CLDX) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$67M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- −100.0% YoY · −100.0% QoQ
- Net income
- −$67M
- −59.2% YoY · +39.3% QoQ
- EPS (diluted)
- −$1.01
- −57.8% YoY · −18.8% QoQ
Source: XBRL data from the Celldex Therapeutics, Inc. (CLDX) Q3 2025 10-Q on SEC EDGAR. USD.
Celldex Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes to risk factors from 10-K dated February 27, 2025
- New Employment Agreement for CCO Teri Lawver with $550K salary, 45% bonus target, severance up to 24 months’ pay post Change in Control
- No new director or officer Rule 10b5-1 or non-Rule 10b5-1 trading plans adopted or terminated this quarter
- Risk factors remain driven by prior 10-K disclosures, likely including clinical and regulatory uncertainties
- No updated financial risk disclosures on liquidity, debt, or currency exposure in current 10-Q
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Celldex Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.